Salute e Benessere

Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision…

i-Ome Cancer marks a significant leap forward in immunoproteomics, providing a rapid and cost-effective approach to characterize the immune system's response to cancer. Cancer is closely associated with protein alterations, which can stimulate the production of autoantibodies. i-Ome Cancer capitalizes on this relationship, enabling the direct identification of disease-associated proteins, offering crucial insights into this devastating disease and its treatment. i-Ome Cancermarks a...
PR Newswire
30/07/2024

ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of…

ALISO VIEJO, Calif., July 30, 2024 /PRNewswire/ -- ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it has received CE (Conformité Européenne) Mark approval in the European Union (EU) for its ViaLase® Laser* for the treatment of adult patients with primary open-angle glaucoma (POAG). ALISO VIEJO, Calif.,July 30, 2024/PRNewswire/ -- ViaLase, Inc ., a clinical-stage medical...
PR Newswire
30/07/2024

Piramal Pharma Solutions Achieves Revenue Threshold on Innovation Work

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, said, "Achieving this threshold is a significant milestone in the history of Piramal Pharma Solutions. For many years, our organizational strategies and tactics have focused on building the expertise and capabilities required to fully support innovator work. This breakthrough validates our efforts and secures our position as an innovator CDMO that support customers in their quest to bring new, patient-centric medicines to…
PR Newswire
30/07/2024

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers…

The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brain These tools have the potential to be used to stratify patients or monitor treatment response for a new generation of future therapies impacting tau pathology in Alzheimer's disease CAMBRIDGE, Mass. and BREA, Calif. and TOKYO, July30, 2024(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio announced a...
Nasdaq GlobeNewswire
30/07/2024

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call…

To access the conference call, please registerhere. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website atir.adctherapeutics.com. The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics...
Nasdaq GlobeNewswire
30/07/2024

GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA

GLP-1 receptor agonists, which mimic the natural hormone glucagon-like peptide released by the stomach after eating, can help people manage diabetes, lose weight and lower their risk of heart disease, stroke and kidney disease. Research in animal models of Alzheimer's disease suggests these drugs may have neuroprotective effects, reduce early forms of amyloid, normalize the brain's processing of glucose, and improve memory and learning. Liraglutide (Novo Nordisk) likely works by multiple…
PR Newswire
30/07/2024

BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy…

Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab Data demonstrated a statistically significant improvement of overall response rate (“ORR”) compared to historical control in patients withanti-PD-(L)1 relapsed/refractory advanced melanoma BioNTech and Regeneron plan to present data from this trial at a forthcoming medical conference; the BNT111 program received a Fast Track...
Nasdaq GlobeNewswire
30/07/2024

Neurosurgery Market to Reach USD 6.8 Billion by 2034, Growth at CAGR 4.5% |…

There is a growing trend towards minimally invasive neurosurgical techniques that offer reduced recovery times and lower risks of complications. The integration of artificial intelligence (AI) and robotics in neurosurgery is improving precision, efficiency, and patient outcomes. There is a growing trend towards minimally invasive neurosurgical techniques that offer reduced recovery times and lower risks of complications. The integration of artificial intelligence (AI) and robotics in...
PR Newswire
30/07/2024

Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped…

The SavvyWire guidewire is engineered to uniquely support multiple steps over the same guidewire, reducing procedural device exchanges, providing stable aortic valve delivery and positioning while continuously monitoring cardiac hemodynamics. Additionally, it has been designed to enable reliable LV pacing without need for adjunct devices or venous access for conventional right ventricular pacing during TAVI procedures. The SavvyWire guidewire is engineered to uniquely support multiple steps...
PR Newswire
30/07/2024

Heart Valve Devices Market to Reach US$ 38.2 Billion by 2034, Driven by Rising…

There is a strong trend towards minimally invasive techniques like transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR), which offer reduced recovery times and lower surgical risks. The development of advanced materials, such as biocompatible polymers and tissue-engineered valves, enhances the performance and durability of heart valve devices. There is a strong trend towards minimally invasive techniques like transcatheter aortic valve replacement (TAVR)...
PR Newswire
30/07/2024

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC…

The adopted recommended wording for the extended indication is: "Slenyto® is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and/or neurogenetic disorders with aberrant diurnal melatonin secretion and /or nocturnal awakenings, where sleep hygiene measures have been insufficient". The adopted recommended wording for the extended indication is: "Slenyto® is indicated for the treatment of insomnia in children and…
PR Newswire
30/07/2024

Nutraceutical Ingredients Market worth $136.1 billion by 2029 - Exclusive Report…

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1319 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1319 Browse in-depth TOC on "Nutraceutical Ingredients Market" 690 – Tables 100 – Figures 610 – Pages Social media's influence has also helped raise people's interest in and knowledge of these ingredients. Social media platforms such as Youtube and Instagram facilitate the rapid sharing of personal testimonials and...
PR Newswire
30/07/2024

Latest Updates on the 7th China International Import Expo Unveiled

Enterprise & Business Exhibition will feature six major exhibition areas: Food and Agricultural Products, Automobiles, Technology Equipment, Consumer Goods, Medical Equipment and Healthcare Products, and Trade in Service, while continuing its commitment to the Innovation Incubation Zone. To date, the total booked exhibition space has exceeded 360,000 square meters. The organization of trade missions and professional visitors is progressing rapidly, with an expected increase in the number of…
PR Newswire
30/07/2024

DEEP Launches a Platform to Build Digital Measures of Health

Traditionally, patient outcomes are measured with subjective questions, doctor interviews or lab results. Including digital measures provides an additional, more continuous, human-centric and objective evidence generation. Traditionally, patient outcomes are measured with subjective questions, doctor interviews or lab results. Including digital measures provides an additional, more continuous, human-centric and objective evidence generation. Technology and Services for Developing Measures...
PR Newswire
30/07/2024

Implantica announces excellent RefluxStop™ investigator initiated study results…

Three months after the RefluxStop™ procedure, symptoms completely resolved or improved in 90% of the patients, PPI consumption was reduced by 84% and Quality of Life GERD-HRQL score was reduced from 32.8 to 6.6, an improvement of 80%, with limited side effects. Three months after the RefluxStop ™procedure, symptoms completely resolved or improved in 90% of the patients, PPI consumption was reduced by 84% and Quality of Life GERD-HRQL score was reduced from 32.8 to 6.6, an improvement of 80%,...
PR Newswire
30/07/2024

Alamar Biosciences Establishes European Headquarters and Distribution Center in…

"We are thrilled to announce the opening of our European headquarters and distribution center in Milan," said Yuling Luo, Ph.D., Chairman, Founder and CEO of Alamar. "This strategic expansion reflects our ongoing commitment to supporting the scientific community across Europe. Milan's dynamic environment and strategic location will allow us to better serve our customers and accelerate the delivery of our innovative solutions." "We are thrilled to announce the opening of…
PR Newswire
30/07/2024

FURNITURE CHINA 2024: From 10-13 September, Setting an Industry Benchmark, "UP"…

Looking Forward to Your VisitEnjoy easier entry to China with eligible visa-free and 72/144 hours transit policies. Register to attend the upcoming Furniture China and Maison Shanghai, from September 10-13, in Pudong, Shanghai! Looking Forward to Your VisitEnjoy easier entry toChinawith eligiblevisa-free and 72/144 hours transit policies. Register to attend the upcomingFurnitureChina andMaison Shanghai, from September 10-13, in Pudong,Shanghai! Stay tuned! Event...
PR Newswire
30/07/2024

European Commission approves Roche's Vabysmo for treatment of retinal vein…

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal drying with VabysmoAdditional submitted data shows that up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four monthsVabysmo is already approved in several countries, including the US and Japan, for RVO and in nearly 100 countries for people...
Nasdaq GlobeNewswire
30/07/2024

Kanazawa University research: High speed atomic force microscopy studies provide…

Previous attempts to understand what possible conformational changes occur during Influenza A viral multiplication cycle had been hindered by what the researchers describe as the "bulky double-helical structure" of the viral RNPs (vRNP, Fig.1 A), which made it hard to see what was going on. As a result the researchers produced a circular recombinant ribonucleoprotein complex (rRNP) (Fig.1 B), which allowed them to overcome the 'bulky issue'. The authors used HS-AFM to follow…
PR Newswire
30/07/2024

Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth

Earlier this year, clinical-stage biotech company BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) made a splash by strategically acquiring a broad clinical development pipeline that included the advanced immunotherapeutics platform technology DPX™. BioVaxys specifically targeted DPX™ as a potential gamechanger in improved mRNA vaccines, multivalent viral vaccines, immune system diseases, and more important to the topic of food allergies, vaccines for desensitizing immune response for peanut…
PR Newswire
29/07/2024

Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August…

Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half 2024 on...
Nasdaq GlobeNewswire
29/07/2024

CSafe launches reusable Silverpod pallet shipper to help pharma companies save…

MONROE, Ohio, July 29, 2024 /PRNewswire/ -- CSafe, the provider of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, has announced the launch of a new reusable pallet shipper - the Silverpod MAX RE - with a host of updated features. The new and improved product will help pharmaceutical customers around the world save on disposal costs, meet their sustainability targets and improve logistical transparency during the shipping journey. MONROE, Ohio,...
PR Newswire
29/07/2024

SAFE - FIRST-HALF 2024 SALES

FIRST-HALF 2024 SALESFleurieux-sur-l'Arbresle-France - July 29, 2024, 6.00 p.m.The group Safe (FR001400F1V2 – ALSAF) announces consolidated sales for 1st half 2024. In k€ First-half 2024*First-half 2023% change Sales 2 5872 909- 11,1% Safe Orthopaedics1 3031 726- 24,5%Safe Medical1 2841 183+ 8,5%* Unaudited 2024 figures The Safe Group's consolidated sales for the 1st half of 2024 came to €2.6 million,...
Nasdaq GlobeNewswire
29/07/2024

Ayurveda Women's Health Market to Reach US$ 7.2 Billion by 2034, Driven by…

Yoga poses, or asanas, are another aspect of Ayurvedic women's health practices that can help with conditions like menstrual cramps and back pain. They benefit women of all ages, but especially pregnant women, by improving posture, strength, and flexibility. Yoga poses, or asanas, are another aspect of Ayurvedic women's health practices that can help with conditions like menstrual cramps and back pain. They benefit women of all ages, but especially pregnant women, by improving posture,...
PR Newswire
29/07/2024
Altri  Comunicati